{
  "id": "f83f9c3c902a6739",
  "title": "Lilly orforglipron helped people maintain weight loss after switching from injectable incretins to oral GLP - 1 therapy in first - of - its - kind Phase 3 trial",
  "description": "20251218T121500Z",
  "content": "",
  "source": "prnewswire.com",
  "source_url": "http://www.prnewswire.com/news-releases/lillys-orforglipron-helped-people-maintain-weight-loss-after-switching-from-injectable-incretins-to-oral-glp-1-therapy-in-first-of-its-kind-phase-3-trial-302645471.html",
  "published_at": "20251218T121500Z",
  "fetched_at": "2025-12-19T00:23:08.544189+00:00",
  "category": "health_biotech",
  "subcategory": null,
  "keywords": [
    "ai"
  ],
  "location": "United States",
  "raw_data": {
    "url": "http://www.prnewswire.com/news-releases/lillys-orforglipron-helped-people-maintain-weight-loss-after-switching-from-injectable-incretins-to-oral-glp-1-therapy-in-first-of-its-kind-phase-3-trial-302645471.html",
    "url_mobile": "",
    "title": "Lilly orforglipron helped people maintain weight loss after switching from injectable incretins to oral GLP - 1 therapy in first - of - its - kind Phase 3 trial",
    "seendate": "20251218T121500Z",
    "socialimage": "",
    "domain": "prnewswire.com",
    "language": "English",
    "sourcecountry": "United States"
  }
}